Thrombo-hemorrhagic liability in children with congenital heart diseases
ConclusionPatients with CHD—both cyanotic and acyanotic—have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Bleeding | Cancer & Oncology | Cardiology | Children | Heart | Heart Disease | Hematology | Stem Cell Therapy | Stem Cells | Study | Thrombosis